Medigen Biotechnology Corp. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 191.57 million compared to TWD 174.87 million a year ago. Net loss was TWD 122.77 million compared to TWD 129.25 million a year ago. Basic loss per share from continuing operations was TWD 0.88 compared to TWD 0.93 a year ago.
For the six months, sales was TWD 676.28 million compared to TWD 360.53 million a year ago. Net loss was TWD 204.48 million compared to TWD 193.35 million a year ago. Basic loss per share from continuing operations was TWD 1.47 compared to TWD 1.39 a year ago.